Answers are grounded in this paper and cite their sources.
Treatment of tenosynovial giant-cell tumors with PLX3397 resulted in a prolonged regression in tumor volume in most patients. (Funded by Plexxikon; ClinicalTrials.gov number, NCT01004861.).
No takes yet. Share an insight, caveat, or question.
Tap et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: